Advice
Following a full submission.
Pramipexole (Mirapexin) is accepted for use within NHS Scotland for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS). It should only be used in patients with a baseline score of 15 points or more on the International Restless Legs Scale (IRLS).
In three double blind placebo-controlled studies pramipexole was associated with a 4 to 9-point improvement on the patient-administered 40-point IRL scale in comparison with placebo based on the core clinical features of the syndrome.
Download detailed advice45KB (PDF)
Medicine details
- Medicine name:
- pramipexole (Mirapexin)
- SMC ID:
- 247/06
- Indication:
- Moderate to severe idiopathic Restless Legs Syndrome
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 May 2006